STING1 and neoplasm: To potentially initiate the oxidative inflammatory cascade conditions against the tumor, we employed the mtBTO NPs to encapsulate the STING agonist (2′,3′-cGAMP) into the mesopores to activate the innate anti-tumor immunity against the tumor [32].